Early detection of Alzheimer's disease: From multiplex assays and imaging to point of care devices and AI-based functional monitoring.

The advent of disease-modifying treatments and risk-reduction strategies in the clinic have increased the demand for biomarkers for early disease detection, prediction of clinical course of disease, individual risk prediction and monitoring of treatment effects. The studies in this special issue span ultra-sensitive fluid assays and automated laboratory platforms, structural and molecular neuroimaging, electrophysiology, digital cognitive and behavioral monitoring, multi-omics, neuromodulation, and the computational frameworks necessary to integrate these diverse data.